Promis Neurosciences (PMN) Earnings Date & Reports

Key Takeaways

• ProMIS Neurosciences reported a third quarter 2026 net loss of $8.2 million, or $(0.89) per share, narrowing from $11.6 million, or $(5.93) per share, in the same period a year earlier.
• The reported net loss per share of $(0.89) came in ahead of the consensus estimate of roughly $(1.26), a modest beat on the bottom line.
• Cash stood at $44.1 million as of September 30, 2026, which management expects to fund operations through 2027 — beyond the anticipated PMN310 data readout.
• Research and development (R&D) expenses fell 32% year over year to $6.7 million as the PMN310 Phase 1b trial moved toward completion of patient visits.
• Management reaffirmed its first quarter 2027 topline data timing for the PRECISE-AD study of PMN310 in Alzheimer's disease.
• For additional context on PMN, explore the Major News, Today's Price Move, Price Targets, and Forecast pages.
• Discover Trending AI Robots to explore AI-driven trading tools and signals.

Earnings Context and Why It Matters

ProMIS Neurosciences is a clinical-stage biotechnology company developing antibody therapies and vaccines that target toxic misfolded proteins linked to neurodegenerative diseases. Its lead candidate, PMN310, is being evaluated in the PRECISE-AD Phase 1b trial for Alzheimer's disease. Because the company generates no product revenue, investors focus on cash runway, expense discipline, and clinical progress rather than traditional sales growth. This quarterly update matters because it signals whether ProMIS can reach its pivotal PMN310 topline readout without additional financing, and whether cost trends support an efficient path toward potential registration-stage studies.

Reported Results

For the third quarter ended September 30, 2026, ProMIS Neurosciences reported a net loss of $8.2 million, or $(0.89) per basic and diluted share, compared with a net loss of $11.6 million, or $(5.93) per share, in the prior-year period. The result beat the consensus estimate of approximately $(1.26) per share.

Research and development (R&D) expenses were $6.7 million, down 32% from $9.8 million a year earlier, driven primarily by a $3.6 million reduction in direct PMN310 costs as the PRECISE-AD trial neared completion of patient visits, partially offset by increased activity in the ALS (amyotrophic lateral sclerosis) and platform programs. General and administrative (G&A) expenses were $1.9 million, roughly flat versus $2.0 million. Other income rose to $0.5 million from $0.2 million on higher interest income.

For the nine months ended September 30, 2026, the net loss was $28.1 million, or $(3.39) per share, compared with $29.0 million, or $(19.58) per share, in the same period of 2025. Cash totaled $44.1 million at quarter-end, up from $6.1 million at December 31, 2025, reflecting net proceeds of $70.1 million from a January 2026 private placement.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking biotechnology names like PMN, it offers a streamlined way to surface comparable opportunities across the sector.

Market Reaction and Investor Sentiment

ProMIS shares had been under pressure heading into the report, trading well below their 52-week high as investors weighed clinical-stage risk and a significant decline over the past year. Following the announcement, shares edged higher in after-hours trading as the narrower-than-expected loss and reaffirmed data timeline provided reassurance. Investor sentiment remains closely tied to the PMN310 program, with price targets reflecting a wide range of outcomes depending on whether the Phase 1b results support advancing toward a registration-stage study. The key near-term risk remains binary clinical data, which can produce sharp moves in either direction.

Forward Outlook and Key Factors to Monitor

The most important catalyst ahead is the PRECISE-AD topline data readout, which management continues to guide for the first quarter of 2027. Investors will watch whether the results support moving PMN310 into a registration-stage study, a decision that will also depend on final data and feedback from the U.S. Food and Drug Administration (FDA).

On the financial side, the company's $44.1 million cash position is expected to fund operations through 2027, reducing near-term dilution risk. However, expense levels could rise if ProMIS advances additional programs, including its ALS and platform initiatives, or begins planning for later-stage development.

Investors should also monitor any updates on subcutaneous dosing and Phase 3 trial design, which management has indicated will be informed by the upcoming data. Broader sentiment around amyloid-targeting Alzheimer's therapies and competitive readouts from peer companies may likewise influence how the market interprets PMN's results.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations